Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02503722 · ClinicalTrials.gov registry record · Phase 1

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

A Phase 1 study of Metastatic Lung Non-Small Cell Carcinoma and Recurrent Lung Non-Small Cell Carcinoma, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 1
Development phase
36
Enrollment target
5
Study locations

NCT02503722: Active Phase 1 study of Metastatic Lung Non-Small Cell Carcinoma and Recurrent Lung Non-Small Cell Carcinoma, sponsored by National Cancer Institute (NCI).

NCT02503722 is a Phase 1 study of Metastatic Lung Non-Small Cell Carcinoma and Recurrent Lung Non-Small Cell Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 36 participants, below the 77-participant average among 39 other Metastatic Lung Non-Small Cell Carcinoma trials with a reported enrollment target (53% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02503722, a Phase 1 study of Metastatic Lung Non-Small Cell Carcinoma and Recurrent Lung Non-Small Cell Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
36 participants
Enrollment target
5
Study locations

Study Summary

This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor. Sapanisertib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Primary Outcome

Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4 (CTCAE v4). CTCAE version 5.0 will be utilized beginning April 1, 2018.

Conditions Studied

Metastatic Lung Non-Small Cell Carcinoma Recurrent Lung Non-Small Cell Carcinoma Stage IV Lung Non-Small Cell Cancer AJCC v7 Stage IIIA Lung Non-Small Cell Cancer AJCC v7 Stage IIIB Lung Non-Small Cell Cancer AJCC v7 Stage III Lung Non-Small Cell Cancer AJCC v7

Interventions

  • DRUG Osimertinib
  • OTHER Laboratory Biomarker Analysis
  • DRUG Sapanisertib
  • OTHER Pharmacological Study

Study Locations (5)

Connecticut

  • Smilow Cancer Center/Yale-New Haven Hospital - New Haven
  • Yale University - New Haven

Florida

  • Moffitt Cancer Center - Tampa

British Columbia

  • BCCA-Vancouver Cancer Centre - Vancouver

Ontario

  • University Health Network-Princess Margaret Hospital - Toronto

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2017-03-23
Est. Completion 2026-06-05
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What the registry record for NCT02503722 still lists

NCT02503722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 77-participant average among 39 other Metastatic Lung Non-Small Cell Carcinoma trials with a reported enrollment target (53% lower).

The record links to 6 conditions, with Metastatic Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Osimertinib is the first listed.

NCT02503722 lists 5 locations in 4 states (Connecticut, Florida, British Columbia).

Frequently Asked Questions

What is clinical trial NCT02503722 about?

NCT02503722 is a clinical study titled "Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer". This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor. Sapanisertib and osimertinib...

What is the current status of trial NCT02503722?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2017-03-23. Estimated completion is 2026-06-05.

What conditions does trial NCT02503722 study?

This clinical trial studies the following conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7.

What interventions are being tested in trial NCT02503722?

The interventions under investigation include: Osimertinib (DRUG), Laboratory Biomarker Analysis (OTHER), Sapanisertib (DRUG), Pharmacological Study (OTHER).

Who is sponsoring clinical trial NCT02503722?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02503722 being conducted?

This trial has 5 study locations across Connecticut, Florida, British Columbia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Lung Non-Small Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02503722's enrollment target sits among peer trials

36 20th of 39 higher than 20 of 39 other Metastatic Lung Non-Small Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Lung Non-Small Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02503722, the US trial registry maintained by the National Library of Medicine. NCT02503722 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.